Additional file 6

A)

Legend:
- ■ Placebo/delayed treatment ⩾2 T2 (n=105)
- ▨ Placebo/delayed treatment 0–1 T2 (n=74)

Y-axis: Proportion of patients with confirmed EDSS progression (%)
X-axis: Year

B)

Legend:
- ■ IFN β-1a 22 μg SC tiw ⩾2 T2 (n=53)
- ▨ IFN β-1a 22 μg SC tiw 0–1 T2 (n=127)

Y-axis: Proportion of patients with confirmed EDSS progression (%)
X-axis: Year

Supplementary Fig. 5 Proportion progressed at each year by ≥2 versus 0–1 active T2 lesions at 12 months.

(a) Placebo/delayed treatment, ≥2 versus 0–1 T2 lesions at 12 months; (b) IFN β-1a 22 µg SC tiw, ≥2 versus 0–1 T2 lesions at 12 months; (c) IFN β-1a 44 µg SC tiw, ≥2 versus 0–1 T2 lesions at 12 months. *p*-values indicate differences between patients with differing lesion loads at 12 months within the treatment group. No statistically significant differences were seen in the placebo/delayed treatment or IFN β-1a 22 µg SC tiw groups. Values were calculated with a logistic-regression model with predictor (≥2 vs. 0–1 T2 lesions) as a fixed effect; number of relapses within the previous 2 years, age, baseline EDSS score, and baseline burden of disease were independent variables, and *p*-values were calculated for the predictive effect of T2 lesion subgroups.

*$p < 0.05$.

EDSS: Expanded Disability Status Scale; IFN β-1a: interferon beta-1a; SC: subcutaneously; tiw: three times weekly.